Literature DB >> 33773357

Predictors and moderators of symptom change during cognitive-behavioral therapy or supportive psychotherapy for body dysmorphic disorder.

Katharine A Phillips1, Jennifer L Greenberg2, Susanne S Hoeppner2, Hilary Weingarden2, Sheila O'Keefe2, Aparna Keshaviah3, David A Schoenfeld2, Sabine Wilhelm2.   

Abstract

BACKGROUND: Research on predictors of treatment outcome in body dysmorphic disorder, a common and severe disorder, is very limited, and no prior studies have examined moderators of outcome. Because treatment is often but not always efficacious, it is important to identify who is more likely to benefit. We examined predictors and moderators of improvement with therapist-delivered cognitive-behavioral therapy versus supportive psychotherapy in the only study of these treatments for body dysmorphic disorder. This report presents secondary analyses from a study whose primary findings have previously been published (Wilhelm et al., 2019).
METHODS: Participants (N=120) with DSM-IV body dysmorphic disorder were randomized to therapist-delivered weekly cognitive-behavioral therapy or supportive therapy for 24 weeks. Using reliable and valid measures, we tested baseline body dysmorphic disorder severity, insight/delusionality, and depression severity as predictors and moderators of overall and treatment modality-specific symptom change. We explored additional variables as predictors and moderators of outcome.
RESULTS: Greater treatment credibility (p=0.02) and presence of obsessive-compulsive personality disorder (p=0.03) predicted greater improvement. Serotonin-reuptake inhibitor treatment at baseline (unchanged during the study) (p=0.01) predicted less improvement. No other variables predicted or moderated outcome (all p>0.05). LIMITATIONS: The study was not powered a priori to detect predictor or moderation effects, which limited our ability to detect them unless they were strong.
CONCLUSIONS: Because greater treatment credibility predicted better outcomes, fostering credibility during therapy may maximize gains. Improvement was not impeded by more severe body dysmorphic disorder, depressive symptoms, or poorer insight. No variables moderated treatment-specific improvement.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Body dysmorphic disorder; Cognitive-behavioral therapy; Moderators; Predictors; Supportive psychotherapy; Treatment

Mesh:

Substances:

Year:  2021        PMID: 33773357      PMCID: PMC8276884          DOI: 10.1016/j.jad.2021.03.011

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  26 in total

1.  A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale.

Authors:  K A Phillips; E Hollander; S A Rasmussen; B R Aronowitz; C DeCaria; W K Goodman
Journal:  Psychopharmacol Bull       Date:  1997

2.  Suicidal ideation and suicide attempts in body dysmorphic disorder.

Authors:  Katharine A Phillips; Meredith E Coles; William Menard; Shirley Yen; Christina Fay; Risa B Weisberg
Journal:  J Clin Psychiatry       Date:  2005-06       Impact factor: 4.384

3.  Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders.

Authors:  Katharine A Phillips; Anthony Pinto; William Menard; Jane L Eisen; Maria Mancebo; Steven A Rasmussen
Journal:  Depress Anxiety       Date:  2007       Impact factor: 6.505

4.  Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders.

Authors:  F Neziroglu; K P Stevens; D McKay; J A Yaryura-Tobias
Journal:  Behav Res Ther       Date:  2001-06

5.  Predictors of Response to Cognitive-Behavioral Therapy for Body Dysmorphic Disorder.

Authors:  Jennifer L Greenberg; Katharine A Phillips; Gail Steketee; Susanne S Hoeppner; Sabine Wilhelm
Journal:  Behav Ther       Date:  2019-01-10

6.  Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder.

Authors:  Anthony Pinto; Michael R Liebowitz; Edna B Foa; H Blair Simpson
Journal:  Behav Res Ther       Date:  2011-05-10

7.  Prediction and moderation of improvement in cognitive-behavioral and psychodynamic psychotherapy for panic disorder.

Authors:  Dianne L Chambless; Barbara Milrod; Eliora Porter; Robert Gallop; Kevin S McCarthy; Elizabeth Graf; Marie Rudden; Brian A Sharpless; Jacques P Barber
Journal:  J Consult Clin Psychol       Date:  2017-06-26

8.  The Brown Assessment of Beliefs Scale: reliability and validity.

Authors:  J L Eisen; K A Phillips; L Baer; D A Beer; K D Atala; S A Rasmussen
Journal:  Am J Psychiatry       Date:  1998-01       Impact factor: 18.112

9.  Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder: A Randomized Clinical Trial.

Authors:  Sabine Wilhelm; Katharine A Phillips; Jennifer L Greenberg; Sheila M O'Keefe; Susanne S Hoeppner; Aparna Keshaviah; Suraj Sarvode-Mothi; David A Schoenfeld
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

10.  Predictors of treatment outcome in modular cognitive therapy for obsessive-compulsive disorder.

Authors:  Gail Steketee; Jedidiah Siev; Jeanne M Fama; Aparna Keshaviah; Anne Chosak; Sabine Wilhelm
Journal:  Depress Anxiety       Date:  2011-02-09       Impact factor: 6.505

View more
  2 in total

1.  Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.

Authors:  Katharine A Phillips; Megan M Kelly
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-11-05

2.  Early response to cognitive behavioral therapy for body dysmorphic disorder as a predictor of outcomes.

Authors:  Jennifer L Greenberg; Nicholas C Jacobson; Susanne S Hoeppner; Emily E Bernstein; Ivar Snorrason; Anna Schwartzberg; Gail Steketee; Katharine A Phillips; Sabine Wilhelm
Journal:  J Psychiatr Res       Date:  2022-06-08       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.